Gamida up on marketing application for blood cancer therapy

Gamida Cell

09/02/2022 14:13

** Shares of Israel-based biopharma co  GMDA.O  rise 3.6% to
$3.2 premarket 
    ** Co says it has started rolling Biologics License
Application (BLA) submission for omidubicel, its experimental
cell therapy for patients with cancers in need of stem cell
transplant  urn:newsml:reuters.com:*:nBw5Dg0qna
    ** Remain on track to complete the BLA submission in Q2 -
GMDA 
    ** Up to Tuesday's close, stock fell 69% in the last 12
months 

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com;))